• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Tafamidis improves all-cause mortality among patients with transthyretin amyloid cardiomyopathy

byShani ChibberandDayton McMillan
September 21, 2018
in Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In a phase 3 randomized control trial, tafamidis was shown to have associations with greater reductions in all-cause mortality and cardiovascular related hospitalizations compared to placebo among participants with transethyretin amyloid cardiomyopathy.

2. The safety profile of tafamidis was comparable to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Transthyretin amyloid cardiomyopathy is a disease that results from deposition of mutant and wild-type transthyretin within the myocardium. Current treatment options for this disease are limited to supportive care with low median survival rates once a diagnosis is made. Tafamidis is a novel transthyretin stabilizer that inhibits the dissociation of protein tetramers into monomers. In early studies it has been shown to slow disease progression for transthyretin amyloid cardiomyopathy. In the Transthyretin Amyloidosis Cardiomyopathy Clinical Trial (ATTR-ACT) the effects of tafamidis versus placebo on all-cause mortality, cardiovascular-related hospitalizations, and safety profile outcomes during the 30-month trial period were evaluated.  Overall, tafamidis treatment resulted in greater reductions in all-cause mortality and cardiovascular-related hospitalizations compared to placebo. Tafamidis was also associated with reduced declines in quality of life and functional capacity compared to placebo. Together these findings suggest that tafamidis could be considered an effective medication for patients with transthyretin amyloid cardiomyopathy.

Click to read the study, published in NEJM

Relevant Reading: Tafamidis in Transthyretin Amyloid Cardiomyopathy: Effects on Transthyretin Stabilization and Clinical Outcomes

RELATED REPORTS

Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis

#VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline

2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]

In-Depth [randomized controlled trial]: This phase 3, multicenter, parallel-group, randomized control trial enrolled 441 patients from 2013-2015 to receive either tafamidis or placebo treatment regimens. Eligible participants were randomized in a 2:1:2 ratio to receive 80mg tafamidis daily, 20mg of tafamidis daily, or placebo. Composite outcomes for each tafamidis group were calculated and compared to placebo. Of the 441 patients initially randomized, 264 patients received tafamidis (either 80mg or 20mg) and 177 received placebo.   All-cause mortality was lower among the tafamidis group (28 of 264, 29.5%) compared to placebo (76 of 177, 42.9%; hazard ratio [HR], 0.70; 95% confidence interval [CI], 0.51 to 0.96). Rates of cardiovascular-related hospitalizations were also lower among the tafamidis group (0.48 vs 0.70 hospitalizations per year, relative risk [RR], 0.68; 95% CI, 0.56 to 0.81). When stratified by New York Heart Association (NYHA) functional classifications, outcomes favored tafamidis except for patients who were in the NYHA class III disease at baseline. In terms of secondary outcomes, tafamidis reduced declines in functional capacity, as assessed by the six-minute walk test (75.68m + 9.24, P<0.001). Tafamidis was also associated with reduced declines in KCCQ-OS quality of life scores compared to placebo (13.65 points + 2.13, P<0.001). The safety profile of tafamidis was deemed comparable to placebo, with most adverse effects characterized as mild to moderate in severity.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

 

 

Previous Post

Fingolimod shows superior efficacy to interferon beta-1a in pediatric multiple sclerosis: the PARADIGMS trial

Next Post

Rivaroxaban does not decrease rates of venous thromboembolism complications after hospital discharge

RelatedReports

Low free sugar diet reduces hepatic steatosis in nonalcoholic fatty liver disease in adolescent males
Chronic Disease

Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis

July 2, 2025
#VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline
StudyGraphics

#VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline

July 2, 2025
2MM: AI Roundup- AI Cancer Test, Smarter Hospitals, Faster Drug Discovery, and Mental Health Tech [May 2nd, 2025]
AI Roundup

2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]

July 2, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

July 2, 2025
Next Post
siRNA against antithrombin alleviates symptoms of hemophilia [PreClinical]

Rivaroxaban does not decrease rates of venous thromboembolism complications after hospital discharge

Childhood ADHD associated with increased risk of suicide [Physician Comment]

2 Minute Medicine Rewind September 24, 2018

Sleep duration inversely related to childhood type 2 diabetes risk makers

Lorcaserin does not increase rate of cardiovascular events in overweight or obese patients

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis
  • #VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline
  • 2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.